EUVIMEDEUVIMED entdecken
Open Access · CC0

A high-throughput inhibitor screen for the erythrocyte plasma membrane Ca++ ATPase

Jonathan Chu, Shreyas Annaswamy, Sanjay A Desai iD

PLOS One · 25.06.2026 · 21 (6) · e0352460

DOI: 10.1371/journal.pone.0352460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 25.06.2026. Verfasst von Jonathan Chu und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryl…. Hauptthemen laut MEDLINE: High-Throughput Screening Assays, Plasma Membrane Calcium-Transporting ATPases, Enzyme Inhibitors, Erythrocyte Membrane. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ubiquitous and conserved plasma membrane Ca ++ ATPase (PMCA) actively extrudes Ca ++ from eukaryotic cells and maintains a large Ca ++ transmembrane gradient that permits diverse roles in signaling and cell cycle regulation. Molecular and biochemical studies have linked PMCA to multiple diseases such as sickle cell disease and malaria severity for the PMCA4b isoform on human erythrocytes. Despite its central role in Ca ++ biology, there are no PMCA inhibitors with sufficient specificity to serve as starting points for therapy development. Because such inhibitors of other ion pumps are critical research tools and are important therapeutics for various diseases, we designed and executed a cell-based high-throughput screen for PMCA inhibitors using human erythrocytes. We miniaturized and optimized a Ca ++ efflux assay using extracellular Fluo-8, a soluble Ca ++ sensitive indicator dye. Ca ++ loading, dye concentration and affinity, hematocrit, and assay temperature were all optimized, providing a robust miniaturized assay for PMCA-mediated Ca ++ efflux. A screen of >52,000 diverse compounds was executed with readings at 2 time points to permit detection of inhibitors with varying affinity; addition of excess extracellular Ca ++ helped exclude false positive fluorescence quenchers. A surprisingly low hit rate, ~ 0.01%, suggests that PMCA has relatively few chemical binding sites that interfere with pump activity. As the screen did not yield reproducible hits, a larger screen with more complex chemical libraries is warranted. The optimized assay should enable identification of specific PMCA inhibitors as research tools and potential future therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Screening AssaysPlasma Membrane Calcium-Transporting ATPasesEnzyme InhibitorsErythrocyte MembraneErythrocytesHumansCalcium

Substanzen

Plasma Membrane Calcium-Transporting ATPasesEnzyme InhibitorsCalcium

Autor:innen und Institutionen

  • The Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America.

ORCID-Profile: Sanjay A Desai

Förderung

  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Chu, J., Annaswamy, S., & Desai, S. A. (2026). A high-throughput inhibitor screen for the erythrocyte plasma membrane Ca++ ATPase. PLOS One, 21(6), e0352460. https://doi.org/10.1371/journal.pone.0352460

Vancouver

Chu J, Annaswamy S, Desai SA. A high-throughput inhibitor screen for the erythrocyte plasma membrane Ca++ ATPase. PLOS One. 2026;21(6):e0352460. doi:10.1371/journal.pone.0352460

BibTeX
@article{Chu2026,
  author = {Chu, Jonathan and Annaswamy, Shreyas and Desai, Sanjay A},
  title = {A high-throughput inhibitor screen for the erythrocyte plasma membrane Ca++ ATPase},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {6},
  pages = {e0352460},
  doi = {10.1371/journal.pone.0352460}
}
Kostenlos starten →